Serum S100ß Levels Are Linked with Cognitive Decline and Peripheral Inflammation in Spinocerebellar Ataxia Type 2.

Experimental and clinical studies have indicated a potential role of the protein S100ß in the pathogenesis and phenotype of neurodegenerative diseases. However, its impact on spinocerebellar ataxia type 2 (SCA2) remains to be elucidated. The objective of the study is to determine the serum levels of S100ß in SCA2 and its relationship with molecular, clinical, cognitive, and peripheral inflammatory markers of the disease. Serum concentrations of S100ß were measured by enzyme-linked immunosorbent assay in 39 SCA2 subjects and 36 age- and gender-matched controls. Clinical scores of ataxia, non-ataxia symptoms, cognitive dysfunction, and some blood cell count-derived inflammatory indices were assessed. The SCA2 individuals manifested S100ß levels similar to the control group, at low nanomolar concentrations. However, the S100ß levels were directly associated with a better performance of cognitive evaluation within the SCA2 cohort. Moreover, the S100ß levels were inversely correlated with most peripheral inflammatory indices. Indeed, the neutrophil-to-lymphocyte ratio significantly mediated the effect of serum S100ß on cognitive performance, even after controlling for the ataxia severity in the causal mediation analysis. Our findings suggested that, within physiologic concentrations, the protein S100ß exerts a neuroprotective role against cognitive dysfunction in SCA2, likely via the suppression of pro-inflammatory mechanisms.

Peripheral Inflammation Links with the Severity of Clinical Phenotype in Spinocerebellar Ataxia 2.

BACKGROUND: The role of peripheral inflammation in spinocerebellar ataxia type 2 (SCA2) is unknown. OBJECTIVE: The objective of this study was to identify peripheral inflammation biomarkers and their relationship with the clinical and molecular features. METHODS: Blood cell count-derived inflammatory indices were measured in 39 SCA2 subjects and their matched controls. Clinical scores of ataxia, nonataxia, and cognitive dysfunction were assessed. RESULTS: The neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the Systemic Inflammation Index (SII), and the Aggregate Index of Systemic Inflammation (AISI) were significantly increased in SCA2 subjects compared with controls. The increases in PLR, SII, and AISI were even observed in preclinical carriers. NLR, PLR, and SII were correlated with the Scale for the Assessment and Rating of Ataxia speech item score rather than with the total score. The NLR and SII were correlated with the nonataxia and the cognitive scores. CONCLUSIONS: Peripheral inflammatory indices are biomarkers in SCA2, which may help to design future immunomodulatory trials and advance our understanding of the disease. © 2023 International Parkinson and Movement Disorder Society.

Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.

Background: Because of high prevalence of Alzheimer's disease (AD) in low- and middle-income countries (LMICs), there is an urgent need for inexpensive and minimally invasive diagnostic tests to detect biomarkers in the earliest and asymptomatic stages of the disease. Blood-based biomarkers are predicted to have the most impact for use as a screening tool and predict the onset of AD, especially in LMICs. Furthermore, it has been suggested that panels of markers may perform better than single protein candidates. Methods: Medline/Pubmed was searched to identify current relevant studies published from January 2016 to December 2020. We included all full-text articles examining blood-based biomarkers as a set of protein markers or panels to aid in AD's early diagnosis, prognosis, and characterization. Results: Seventy-six articles met the inclusion criteria for systematic review. Majority of the studies reported plasma and serum as the main source for biomarker determination in blood. Protein-based biomarker panels were reported to aid in AD diagnosis and prognosis with better accuracy than individual biomarkers. Conventional (amyloid-beta and tau) and neuroinflammatory biomarkers, such as amyloid beta-42, amyloid beta-40, total tau, phosphorylated tau-181, and other tau isoforms, were the most represented. We found the combination of amyloid beta-42/amyloid beta-40 ratio and APOEε4 status to be most represented with high accuracy for predicting amyloid beta-positron emission tomography status. Conclusion: Assessment of Alzheimer's disease biomarkers in blood as a non-invasive and cost-effective alternative will potentially contribute to early diagnosis and improvement of therapeutic interventions. Given the heterogeneous nature of AD, combination of markers seems to perform better in the diagnosis and prognosis of the disease than individual biomarkers.

Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives.

Polyglutamine spinocerebellar ataxias (SCAs) comprise a heterogeneous group of six autosomal dominant ataxias caused by cytosine-adenine-guanine repeat expansions in the coding region of single genes. Currently, there is no curative or disease-slowing treatment for these disorders, but their monogenic inheritance has informed rationales for development of gene therapy strategies. In fact, RNA interference strategies have shown promising findings in cellular and/or animal models of SCA1, SCA3, SCA6, and SCA7. In addition, antisense oligonucleotide therapy has provided encouraging proofs of concept in models of SCA1, SCA2, SCA3, and SCA7, but they have not yet progressed to clinical trials. On the contrary, the gene editing strategies, such as the clustered regularly interspaced short palindromic repeat (CRISPR/Cas9), have been introduced to a limited extent in these disorders. In this article, we review the available literature about gene therapy in polyglutamine SCAs and discuss the main technological and ethical challenges toward the prospect of their use in future clinical trials. Although antisense oligonucleotide therapies are further along the path to clinical phases, the recent failure of three clinical trials in Huntington's disease may delay their utilization for polyglutamine SCAs, but they offer lessons that could optimize the likelihood of success in potential future clinical studies. © 2021 International Parkinson and Movement Disorder Society.

Caracterización molecular de cepas de Pasteurella multocida aisladas del ganado bovino / Molecular characterization of Pasteurella multocida strains from cattle

La Pasteurelosis es una enfermedad producida por la bacteria Pasteurella multocida miembro del género Pasteurella, que afecta a una gran variedad de animales domésticos y salvajes. La bacteria se caracteriza por ser Gram negativa, inmóvil, cocobacilar y anaerobia facultativa. La aplicación de métodos genotípicos resulta de gran utilidad y permiten superar limitaciones de los procedimientos fenotípicos tradicionales. El objetivo de este trabajo fue determinar la relación genética entre las cepas B1, B2 y B3 de P. multocida propuestas como candidatos vacunales. Las cepas procedieron del cepario de la Empresa Productora de Vacunas Virales y Bacterianas, que pertenece a los Laboratorios LABIOFAM. Las cepas en estudio fueron analizadas con las técnicas moleculares de Reacción en Cadena de la Polimerasa y electroforesis en campo pulsado. Se pudo confirmar que las tres cepas pertenecían a la especie P. multocida, subespecie multocida tipo capsular A. De igual manera se detectó que las cepas B1 y B3 son indistinguibles genéticamente entre sí y que la B2 poseía un 91 por ciento de similitud con respecto a las dos primeras. Los resultados obtenidos mediante la identificación y clasificación de estas cepas, permitirán el desarrollo de vacunas contra P. multocida(AU)

Pasteurellosis is a disease caused by Pasteurella multocida bacterium, which affects a variety of domestic and wild animals. P. multocida is a Gram negative, non-motile, and facultative anaerobic cocobacillus, from genus Pasteurella. Genotyping methods are useful to improve the limitations of the traditional phenotyping methods. The aim of this paper was to determine the genetic relationship between P. multocida strains B1, B2 and B3, proposed as vaccine candidates. The strains came from the culture collection of the Viral and Bacterial Vaccine Producing Enterprise, LABIOFAM (acronym in Spanish), and were analyzed with polymerase chain reaction and pulsed field electrophoresis. It was confirmed that the three strains belonged to P. multocida species, capsular type A multocida subspecies. It was also proved that B1 and B3 strains are genetically indistinguishable, and that B2 had a 91percent of similarity with B1 and B3. Results obtained by the identification and classification of these strains will permit the development of vaccines against P. multocida(AU)